United Therapeutics Corporation (OQ:UTHR)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 1000 SPRING ST
Tel: N/A
Website: https://www.unither.com
IR: See website
Key People
Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Michael Benkowitz
President, Chief Operating Officer
James C. Edgemond
Chief Financial Officer, Treasurer
Paul A. Mahon
Executive Vice President, General Counsel, Corporate Secretary
Business Overview
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind's Afrezza (insulin human) Inhalation Powder.
Financial Overview
For the fiscal year ended 31 December 2023, United Therapeutics Corporation revenues increased 20% to $2.33B. Net income increased 35% to $984.8M. Revenues reflect Orenitram segment increase of 11% to $359.4M, Unituxin segment increase of 9% to $198.9M, United States segment increase of 21% to $2.2B, Rest of World segment increase of 3% to $125.3M. Net income benefited from Interest Income increase from $45.2M to $162.7M (income).
Employees: 1,168 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $8,324M as of Dec 31, 2023
Annual revenue (TTM): $2,328M as of Dec 31, 2023
EBITDA (TTM): $1,242M as of Dec 31, 2023
Net annual income (TTM): $984.80M as of Dec 31, 2023
Free cash flow (TTM): $747.60M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 47,058,545 as of Feb 14, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.